One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a a ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...